Modus poster presented at EHA Congress

Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with Sickle Cell Disease, presented a poster at the European Hematology Association Congress in Copenhagen.

Modus Therapeutics’s submission was entitled: ‘Sevuparin Demonstrates Binding to Key Adhesion Receptors Involved in Pathogenesis of Sickle-Cell Disease’ under session for non-malignant hematopoetic disorders.

The 21st Congress of the European Hematology Association took place on 9-12 June 2016 at The Bella Center, Center Boulevard 5, Copenhagen. The poster (P756) was presented by Dr. Maria Lindgren.

Modus Therapeutics is currently enrolling SCD patients into a multi-centre, international, randomised Phase II study in Europe and the Middle East (NCT02515838).